Prognosis of Patients With Interstitial Lung Disease Induced by Different Pharmacological Types of Anticancer Drugs

Anticancer Res. 2021 May;41(5):2563-2568. doi: 10.21873/anticanres.15034.

Abstract

Background/aim: The aim of this study was to evaluate the effect of drug-induced interstitial lung disease (DILD) on treatment outcomes by comparing the mortality of patients with DILD induced by different pharmacological types of anticancer drugs.

Patients and methods: Japanese patients with lung cancer who had received chemotherapy at Fujita Health University Hospital were enrolled. The primary outcome was the short-term mortality rate from the administration of chemotherapy that might have caused DILD.

Results: Eleven, 16, and 20 patients with DILD were assigned to the kinase inhibitor (KI), immune-checkpoint inhibitor (ICI), and cytotoxic anticancer drug groups, respectively. The 90-day mortality rate after the DILD event in the group treated with cytotoxic anticancer drugs was significantly higher than in the KI and ICI groups.

Conclusion: Patients with DILD induced by cytotoxic anticancer drugs have poorer prognoses than those with DILD induced by KIs or ICIs.

Keywords: Kinase inhibitor; cytotoxic anticancer drug; immune-checkpoint inhibitor; interstitial lung disease.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cytotoxins / administration & dosage
  • Cytotoxins / adverse effects
  • Drug Therapy
  • Drug-Related Side Effects and Adverse Reactions / mortality*
  • Drug-Related Side Effects and Adverse Reactions / pathology
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / administration & dosage
  • Immune Checkpoint Inhibitors / adverse effects
  • Lung Diseases, Interstitial / chemically induced
  • Lung Diseases, Interstitial / drug therapy
  • Lung Diseases, Interstitial / mortality*
  • Lung Diseases, Interstitial / pathology
  • Male
  • Middle Aged
  • Neoplasms / classification
  • Neoplasms / complications
  • Neoplasms / drug therapy
  • Neoplasms / mortality*
  • Prognosis
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects

Substances

  • Cytotoxins
  • Immune Checkpoint Inhibitors
  • Protein Kinase Inhibitors